LOCALLY ADVANCED SOLID TUMORS
Clinical trials for LOCALLY ADVANCED SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED SOLID TUMORS trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug targets genetic flaws in Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called repotrectinib (TPX-0005) in people with advanced solid tumors that have certain genetic changes (ALK, ROS1, or NTRK). The goal is to see if the drug is safe and can shrink tumors. About 500 adults will take part, first to find the best dose, the…
Matched conditions: LOCALLY ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 10:33 UTC
-
New hope for Hard-to-Treat cancers: early trial launches
Disease control Recruiting nowThis early-phase study tests a new experimental drug, RO7566802, alone or combined with another drug (atezolizumab) in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety and find the right dose. About 250 part…
Matched conditions: LOCALLY ADVANCED SOLID TUMORS
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated May 26, 2026 10:29 UTC
-
New hope for kids with rare cancers: targeted drug trial opens
Disease control Recruiting nowThis study tests a drug called repotrectinib in children and young adults (up to age 25) with advanced cancers that have specific genetic changes (ALK, ROS1, or NTRK). The first part finds the safest dose, and the second part checks if the drug shrinks tumors. About 75 participan…
Matched conditions: LOCALLY ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated May 19, 2026 12:01 UTC